Learning objective
Compare agonist, partial-agonist and antagonist treatment mechanisms without inferring an individual treatment plan.
Mechanism and time course together
The readable treatment capture compares full-agonist substitution, partial-agonist substitution and antagonism. Receptor action is only one part of the explanation: onset, duration, formulation and treatment context also matter. A slower, more sustained exposure can differ from a rapid peak even when the receptor family is the same.
Compare three strategies
A full agonist activates the relevant receptor system; methadone is the chapter’s opioid example. A partial agonist produces lower maximal activation than a full agonist in the specified system; buprenorphine is the opioid example and varenicline illustrates partial agonism at nicotinic receptors. An antagonist blocks agonist activation; naltrexone is the chapter’s maintenance-treatment example. These examples classify mechanisms rather than rank choices for a person.
Repair terminology, preserve the source boundary
The page 53 description of partial agonists as “less potent” should not replace Chapter 3’s distinction: partial agonism concerns efficacy, while potency concerns the concentration needed for an effect. Also distinguish acute overdose reversal from ongoing treatment; the same broad receptor label does not make clinical roles interchangeable. We do not reproduce the capture’s mixed antagonist list as a pure-antagonist classification.
Learning and support remain relevant
The chapter discusses psychological treatment alongside pharmacological approaches because cues, coping, environment and behavior remain part of the problem. Medication mechanism alone is not a complete account of recovery. Page 54 is largely blank in the supplied PDF, so vaccine and other missing treatment discussions are not claimed as read or fully covered. The existing visual atlas labels separately sourced investigational mechanisms.
| Strategy | Receptor-level idea | Study example |
|---|---|---|
| Full agonist | Activates the receptor system with full agonist efficacy in the comparison. | Methadone in the chapter’s opioid discussion. |
| Partial agonist | Activates with a lower maximal response in the same system. | Buprenorphine; varenicline at nicotinic receptors. |
| Antagonist | Occupies receptors and blocks agonist activation. | Naltrexone in the chapter’s treatment discussion. |
Check your understanding
Comprobación complementaria
Original PolyDiscipline practice based on the explanation and cited sources. Unscored; answers are temporary to this page visit and do not award mastery or XP.
Comprobación complementaria
Original PolyDiscipline practice based on the explanation and cited sources. Unscored; answers are temporary to this page visit and do not award mastery or XP.
Explain it without notes
Why is a partial agonist not simply “a weak dose of a full agonist”?
Compare your explanation 1
At higher concentrations it still has a lower maximum in the same tested system. A low dose of a full agonist can produce a small effect without changing that drug’s attainable maximum.
What prevents a receptor table from being a complete treatment plan?
Compare your explanation 2
Clinical indication, time course, individual circumstances, safety, adherence and behavioral context also matter. Mechanism categories alone do not determine a plan.
Revisit the connected course lessons and visuals
Julien’s Primer of Drug Action, supplied consolidated PDF pages 51, 52, 53, 54, 55 (Chapter 4). Locators refer to PDF captures, not printed pages. Original paraphrase and practice; source conformance reviewed, not independently clinically certified. Professor or supplementary clarifications are identified in the lesson and source list. Page 54 is a missing capture, not a source for treatment claims.